Prostate cancer trials in New Zealand
10 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Dunedin, Tauranga
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 3Taking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Auckland, Christchurch, Hamilton, Tauranga
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 1/2Taking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Roslyn, Wellington
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - Phase 3Taking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Auckland, Dunedin
- Age
- 18 years and over
- People
- 1,314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - Phase 3Taking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Auckland, Christchurch, Hamilton, Palmerston North, Tauranga
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - Phase 1/2Taking peopleA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Auckland
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Grafton, Hamilton
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Where
- Christchurch, Grafton
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- Telix Pharmaceuticals (Innovations) Pty Limited
See details and how to joinNCT06520345 - No phaseTaking peoplePredictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
- Where
- Auckland
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- Gabriela Ilie
See details and how to joinNCT04895839 - Phase 3Taking peopleA Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
- Where
- Auckland
- Age
- 18 years and over
- People
- 1,128 worldwide
- Run by
- Institute of Cancer Research, United Kingdom
See details and how to joinNCT05613023